Mein Warenkorb

Fas

Fas Molekülinformation

Englischer NameApoptosis-mediating surface antigen FASAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel1Target-AliasTumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameApoptosis-mediating surface antigen FAS
Target-AliasTumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved

Fas Produktliste

  • Attribut

    Protein (2)

  • Produktbibliothek

    Online (2)

  • Spezies

    Human (2)

  • Etikett

    Fc Tag (1)His Tag (1)

  • Marker

    Unconjugated (2)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
Human
HEK293
Human Fas / TNFRSF6 / CD95 Protein, His Tag (MALS verified)
In den Warenkorb legen
Human
HEK293
Human Fas / TNFRSF6 / CD95 Protein, Fc Tag (MALS verified)
In den Warenkorb legen
Gesamtmenge2
  • 1

Fas Molekülhintergrund

The Fas is also known as FAS receptor (FasR), apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6). is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being the mitochondrial pathway. FasR is located on chromosome 10 in humans and 19 in mice. Similar sequences related by evolution (orthologs) are found in most mammals. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. Recently, Fas has also been shown to promote tumor growth, since during tumor progression, it is frequently downregulated or cells are rendered apoptosis resistant. Cancer cells in general, regardless of their Fas apoptosis sensitivity, depend on constitutive activity of Fas. This is stimulated by cancer-produced Fas ligand for optimal growth.

Fas Molekülalias

FAS,ALPS1A,APO1,APT1,CD95,FAS1,FASTM,TNFRSF6,FasR

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
XelafaslatideONL-1204Phase 2 ClinicalOnl TherapeuticsGeographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
KanglaiteApprovedZhejiang Kanglaite Pharmaceutical Co LtdKanglaiteMainland ChinaLiver Neoplasms; Carcinoma, Non-Small-Cell LungZhejiang Kanglaite Pharmaceutical Co Ltd1997-01-01Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours
Details

Produktrezensionen

  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns